Payment overview · 2025
General Payments
$75.08
3 reported records · 2 companies
Healthcare provider profile · identity verified
John Michael Tucker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLESTON, SC · NPI 1154741056
Verified facts
What the public records show
CMS Open Payments records show John Michael Tucker, MD received $75.08 in general payments during 2025 across 3 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 63.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $47.49 | 63.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.59 | 36.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $75.08 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 929 | 275 |
| Amlodipine Besylate | Amlodipine Besylate | 597 | 188 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 505 | 147 |
| Losartan Potassium | Losartan Potassium | 430 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 96 |
| Omeprazole | Omeprazole | 284 | 107 |
| Gabapentin | Gabapentin | 239 | 71 |
| Mounjaro | Tirzepatide | 197 | 35 |
| Famotidine | Famotidine | 190 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 63 |
| Eliquis | Apixaban | 180 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 58 |
| Lisinopril | Lisinopril | 171 | 55 |
| Metformin Hcl | Metformin Hcl | 143 | 48 |
| Meloxicam | Meloxicam | 141 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 42 |
| Furosemide | Furosemide | 134 | 46 |
| Allopurinol | Allopurinol | 132 | 38 |
| Ozempic | Semaglutide | 129 | 32 |
| Ezetimibe | Ezetimibe | 128 | 46 |
| Sertraline Hcl | Sertraline Hcl | 127 | 42 |
| Spironolactone | Spironolactone | 120 | 42 |
| Jardiance | Empagliflozin | 119 | 30 |
| Finasteride | Finasteride | 108 | 36 |
| Carvedilol | Carvedilol | 99 | 33 |
| Alendronate Sodium | Alendronate Sodium | 98 | 33 |
| Metformin Hcl Er | Metformin Hcl | 97 | 34 |
| Tramadol Hcl | Tramadol Hcl | 94 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 30 |
| Trazodone Hcl | Trazodone Hcl | 88 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 36 |
| Montelukast Sodium | Montelukast Sodium | 81 | 24 |
| Chlorthalidone | Chlorthalidone | 79 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 19 |
| Valsartan | Valsartan | 76 | 25 |
| Clonazepam | Clonazepam | 73 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 23 |
| Celecoxib | Celecoxib | 69 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 34 |
| Potassium Chloride | Potassium Chloride | 68 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | suppressed |
| Irbesartan | Irbesartan | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | 15 |
| Repatha Sureclick | Evolocumab | 54 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 16 |
| Myrbetriq | Mirabegron | 48 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 11 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Simvastatin | Simvastatin | 43 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Atenolol | Atenolol | 40 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 13 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Azelastine Hcl | Azelastine Hcl | 31 | 14 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 26 |
| Pregabalin | Pregabalin | 28 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 12 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Naproxen | Naproxen | 26 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 26 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Ramipril | Ramipril | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Emsam | Selegiline | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $75.08 · 3 records | Teva Pharmaceuticals USA, Inc. | AJOVY, AUSTEDO XR, PAXLOVID | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error